Obviousness-type double patenting: best IP practices for international practitioners in view of In re: Cellect, LLC
An update from CET 5 Biotechnology and Pharmaceuticals
28 Nov 2023
0
In its late August 2023 decision in In re: Cellect, LLC, the US Federal Circuit resolved a question that has lingered since the US Congress’s 1999 enactment of patent term adjustment. Nos. 2022-1293, 2022-1294, 2022-1295, 2022-1296 (Fed. Cir. August 28, 2023). The court held that patent term-adjusted patents are subject to obviousness-type double patenting...
What's the point of filing a patent if I can't afford to enforce it? When I...
READ MORE
The main obstacles to obtain patent protection for CAR-T cell-related technologies in Brazil
15 Nov 2023
0
As research and development efforts move forward in relation to Chimeric antigen receptor CAR-T cells, it is...
READ MORE
Genome editing using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated 9 (Cas-9) technology holds great potential...
READ MORE
This case study follows on from Ian Gill’s recent blog and book review on the productivity...
READ MORE
Since the widespread use of emails began in the 1990s, the average efficiency of the knowledge...
READ MORE
The new Indian Biodiversity Law - a significant step towards encouraging science and innovation in the...
READ MORE
Chimeric antigen receptor (CAR) T-cell therapy is a personalised cancer treatment that is gaining greater visibility...
READ MORE
Combatting the backlog in Brazil - prioritising the examination of patent applications
16 Aug 2023
0
In recent years, the Patent Board of the Brazilian Patent and Trademark Office (National Institute of...
READ MORE
BECOME A MEMBER OF FICPI
FICPI is the only international NGO whose membership consists exclusively of IP attorneys in private practice. As a result, the FICPI community is driven by a shared interest to promote solutions and advocacy for private IP practitioners.